GPT-Rosalind (OpenAI) vs Augment Code Intent
Which one should you pick? Here's the full breakdown.
GPT-Rosalind (OpenAI)
OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)
Augment Code Intent
Spec-driven multi-agent orchestration for code -- coordinator + implementor agents in isolated git worktrees + verifier. Works with Augment's Auggie, Claude Code, Codex, and OpenCode. Public beta 2026-02-10
| Category | GPT-Rosalind (OpenAI) | Augment Code Intent |
|---|---|---|
| Ease of Use | 3.0 | 7.0 |
| Output Quality | 9.0 | 8.0 |
| Value | 7.0 | 8.0 |
| Features | 8.0 | 9.0 |
| Overall | 6.8 | 8.0 |
Pricing Comparison
| Feature | GPT-Rosalind (OpenAI) | Augment Code Intent |
|---|---|---|
| Free Tier | No | No |
| Starting Price | Invite only | Included in Auggie subscription |
Which Should You Pick?
Pick GPT-Rosalind (OpenAI) if...
- ✓Higher output quality (9 vs 8)
Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.
Visit GPT-Rosalind (OpenAI)Pick Augment Code Intent if...
- ✓Easier to use (7 vs 3)
- ✓Better value for money (8/10)
- ✓More features (9 vs 8)
Engineering teams already using Augment Code's Auggie or running mixed Claude-Code + Codex workflows who want higher-level orchestration than writing LangGraph graphs from scratch. Also teams that want git-worktree-isolated parallel agent work with a verifier in the loop.
Visit Augment Code IntentOur Verdict
Augment Code Intent is the clear winner here with 8.0/10 vs 6.8/10. GPT-Rosalind (OpenAI) isn't bad, but Augment Code Intent outperforms it across the board. Pick GPT-Rosalind (OpenAI) only if researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access.